Your browser doesn't support javascript.
loading
Prognostic factors in patients with primary cutaneous anaplastic large cell lymphoma: a multicentric, retrospective analysis of the Spanish Group of Cutaneous Lymphoma.
Fernández-de-Misa, R; Hernández-Machín, B; Combalía, A; García Muret, M P; Servitje, O; Muniesa, C; Gallardo, F; Pujol, R M; Martí, R M; Ortiz-Brugués, A; Maroñas-Jiménez, L; Ortiz-Romero, P L; Blanch Rius, L; Izu, R; Román, C; Cañueto, J; Blanes, M; Morillo, M; Bastida, J; Peñate, Y; Pérez Gala, S; Espinosa Lara, P; Pérez Gil, A; Estrach, T.
Afiliación
  • Fernández-de-Misa R; Department of Dermatology and Research Unit, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain.
  • Hernández-Machín B; Department of Dermatology, Sefton Suite, DMC Healthcare, NHS Trust Liverpool, Liverpool, UK.
  • Combalía A; Department of Dermatology, Hospital Clínico, University of Barcelona, Barcelona, Spain.
  • García Muret MP; Department of Dermatology, Hospital Santa Creu i Sant Pau, UAB, Barcelona, Spain.
  • Servitje O; Department of Dermatology, Hospital Universitari de Bellvitge, IDIBELL, Barcelona, Spain.
  • Muniesa C; Department of Dermatology, Hospital Universitari de Bellvitge, IDIBELL, Barcelona, Spain.
  • Gallardo F; Department of Dermatology, Hospital del Mar, Universitat Autónoma de Barcelona, Barcelona, Spain.
  • Pujol RM; Department of Dermatology, Hospital del Mar, Universitat Autónoma de Barcelona, Barcelona, Spain.
  • Martí RM; Department of Dermatology, Hospital Univeritari Arnau de Vilanova, IRBLleida, Lleida, Spain.
  • Ortiz-Brugués A; Centre of Biomedical Research on Cancer (CIBERONC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
  • Maroñas-Jiménez L; Department of Dermatology, Hospital Univeritari Arnau de Vilanova, IRBLleida, Lleida, Spain.
  • Ortiz-Romero PL; Department of Dermatology, Hospital Universitario 12 de Octubre, i+12 Research Institute, Universidad Complutense, Madrid, Spain.
  • Blanch Rius L; Centre of Biomedical Research on Cancer (CIBERONC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
  • Izu R; Department of Dermatology, Hospital Universitario 12 de Octubre, i+12 Research Institute, Universidad Complutense, Madrid, Spain.
  • Román C; Department of Dermatology, Hospital de Basurto, Bilbao, Spain.
  • Cañueto J; Department of Dermatology, Hospital de Basurto, Bilbao, Spain.
  • Blanes M; Department of Dermatology, Hospital Universitario de Salamanca, Salamanca, Spain.
  • Morillo M; Department of Dermatology, Hospital Universitario de Salamanca, Salamanca, Spain.
  • Bastida J; Department of Dermatology, Hospital General Universitario de Alicante, Alicante, Spain.
  • Peñate Y; Department of Dermatology, Hospital Universitario Virgen del Rocío, Sevilla, Spain.
  • Pérez Gala S; Department of Dermatology, Hospital Universitario Dr. Negrín, Las Palmas de Gran Canaria, Spain.
  • Espinosa Lara P; Department of Dermatology, Complejo Hospitalario Universitario Insular Materno-Infantil, Las Palmas de G.C, Spain.
  • Pérez Gil A; Department of Dermatology, Hospital Universitario Ramón y Cajal, Madrid, Spain.
  • Estrach T; Department of Dermatology, Hospital Universitario Infanta Cristina, Parla, Madrid, Spain.
J Eur Acad Dermatol Venereol ; 34(4): 762-768, 2020 Apr.
Article en En | MEDLINE | ID: mdl-31591786
ABSTRACT

BACKGROUND:

Reliable prognostic factors for patients with primary cutaneous anaplastic large cell lymphoma (PCALCL) are lacking.

OBJECTIVE:

To identify prognostic factors for specific survival in patients with PCALCL.

METHODS:

Using the convenience sampling method, patients with PCALCL diagnosed from May 1986 to August 2017 in 16 University Departments were retrospectively reviewed.

RESULTS:

One hundred eight patients were included (57 males). Median age at diagnosis was 58 years. All of them showed T1-3N0M0 stages. Seventy per cent of the cases presented with a solitary lesion, mostly at the limbs. Complete response rate after first-line treatment was 87%, and no advantage was observed for any of them (surgery, radiotherapy, chemotherapy or other approaches). Nodal and visceral progression rate was 11% and 2%, respectively. 5-year specific survival (SSV) reached 93%; 97% for T1 patients and 84% for T2/T3 patients (P = 0.031). Five-year SSV for patients developing early cutaneous relapse was 64%; for those with late or no relapse, 96% (P = 0.001). Estimated median SSV for patients showing nodal progression was 103 months (95% CI 51-155 months); for patients without nodal progression, estimated SSV did not reach the median (P < 0.001). Nodal progression was an independent predictive parameter for shorter survival (P = 0.011).

CONCLUSION:

Multiple cutaneous lesions at presentation, early skin relapse and nodal progression portrait worse prognosis in patients with PCALCL.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Asunto principal: Linfoma Anaplásico Cutáneo Primario de Células Grandes Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: J Eur Acad Dermatol Venereol Asunto de la revista: DERMATOLOGIA / DOENCAS SEXUALMENTE TRANSMISSIVEIS Año: 2020 Tipo del documento: Article País de afiliación: España

Texto completo: 1 Colección: 01-internacional Asunto principal: Linfoma Anaplásico Cutáneo Primario de Células Grandes Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: J Eur Acad Dermatol Venereol Asunto de la revista: DERMATOLOGIA / DOENCAS SEXUALMENTE TRANSMISSIVEIS Año: 2020 Tipo del documento: Article País de afiliación: España